GSK is discontinuing camlipixant’s refractory chronic cough program after mixed Phase III results, a negative development for pipeline momentum. The asset is still active in a Phase IIb study for irritable bowel syndrome, limiting the overall setback to the cough indication rather than a full program exit.
GSK is discontinuing camlipixant’s refractory chronic cough program after mixed Phase III results, a negative development for pipeline momentum. The asset is still active in a Phase IIb study for irritable bowel syndrome, limiting the overall setback to the cough indication rather than a full program exit.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
moderately negative
Sentiment Score
-0.35
Ticker Sentiment
